Eli Lilly to Acquire Kelonia for Up to $7 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Should l Buy LLY?
Eli Lilly and Kelonia Therapeutics announced a definitive agreement for Lilly to acquire Kelonia. Under the terms of the agreement, Lilly will acquire Kelonia, and Kelonia shareholders will receive up to $7B in cash, inclusive of an upfront payment of $3.25B, and subsequent payments upon achievement of certain clinical, regulatory and commercial milestones. The transaction is subject to customary closing conditions, including customary regulatory approvals, and is expected to close in the second half of 2026. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance. For Lilly, Kirkland & Ellis LLP is acting as legal counsel. For Kelonia, Jefferies LLC is acting as financial advisor, and Goodwin Procter LLP is acting as legal counsel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 868.270
Low
950.00
Averages
1192
High
1500
Current: 868.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Expected to Report Strong Q1 Earnings Growth
- Earnings Expectations: Eli Lilly is projected to report Q1 EPS of $6.85 with a 40.3% year-over-year revenue increase to $17.86 billion, indicating strong performance in the obesity treatment market that could drive stock price up.
- Drug Catalysts: Analysts believe that obesity drugs Mounjaro and Zepbound will anchor Lilly's medium-term growth, while the approval of Foundayo and the $7 billion acquisition of Kelonia Therapeutics serve as near-term catalysts that may enhance market confidence.
- Management Guidance: Analyst Stephen Ayers is keenly awaiting management's reaffirmation of the 2026 revenue guidance, as maintaining the current outlook may signal strong market performance for Foundayo, whereas a revision to the lower end could indicate pricing erosion or lagging uptake.
- Market Dynamics: Despite a more than 17% decline in Eli Lilly's stock this year, the company has beaten EPS and revenue estimates 100% of the time over the past two years, maintaining a positive outlook for future performance.
See More
Hims CEO's Pay Gap Sparks Attention Ahead of Vote
- Compensation Structure Analysis: Hims CEO Andrew Dudum's compensation of $22.96 million, down 7% from last year, remains 272 times the median employee pay, highlighting a significant pay gap that may impact the company's governance image.
- Performance Target Achievement: Hims met 94% of its revenue target and 98% of its adjusted EBITDA target last year, resulting in executives receiving 93.72% of their annual incentive bonuses, reflecting stable performance in the highly competitive GLP-1 weight-loss market.
- Stock Award Details: Dudum received 306,406 restricted stock units (RSUs) and performance-based stock options, with options convertible into 278,622 shares at minimum performance and up to 1.39 million shares at maximum performance, indicating the company's focus on long-term incentives.
- Intensifying Market Competition: Hims faces increasing competition in the GLP-1 market from Amazon and other digital platforms, recently expanding access to branded treatments from Novo Nordisk and Eli Lilly to enhance market share and address regulatory pressures.
See More
The Future of AI in Healthcare Applications
- AI in Health Management: Alex Zhavoronkov, founder of Insilico Medicine, advocates for increased consumer use of AI to answer basic health questions like dietary advice, which can save time with doctors and enhance health management efficiency.
- Innovative Health Tools: OpenAI's ChatGPT Health and Amazon's Health AI tools aim to provide data-driven health advice by securely connecting medical records and wellness apps, although these tools are not intended for diagnosis or treatment.
- Accelerated Drug Development: Zhavoronkov notes that AI tools reduce the drug development candidate stage to 18 months, significantly improving efficiency compared to the traditional four years, highlighting AI's immense potential in the pharmaceutical industry.
- Importance of Human Collaboration: Shreehas Tambe from Biocon emphasizes the necessity of
See More
The Future of AI in Healthcare Applications
- AI Health Q&A: Alex Zhavoronkov, CEO of Insilico Medicine, emphasizes that AI can answer basic health questions like dietary advice, thereby saving time spent with doctors and enhancing consumer health management efficiency.
- New Tool Launches: OpenAI and Amazon launched health tools in January, with ChatGPT Health allowing secure connections to medical records, while Amazon's HealthAI provides advice based on medical records and lab results, advancing AI applications in consumer healthcare.
- Reduced R&D Time: Zhavoronkov noted that AI tools cut drug development time to 18 months, significantly improving efficiency compared to the traditional four years, which has crucial strategic implications for the pharmaceutical industry.
- Importance of Human Oversight: Shreehas Tambe, CEO of Biocon, stresses the need for AI models to be validated by professionals to ensure their effectiveness in drug discovery, avoiding erroneous results due to users' unfamiliarity with the technology.
See More
Eli Lilly's Dominance in Weight-Loss Drug Market
- Market Leadership: Eli Lilly's dominance in the weight-loss drug market positions it well for future growth, with projections indicating significant expansion over the next decade, although some investors remain skeptical about its ability to deliver superior returns in the next five years.
- Analyst Optimism: Morgan Stanley analyst Terence Flynn reiterated a 'buy' rating on Eli Lilly stock with a price target of $1,327, suggesting a potential upside of about 52% from the current price of $870, which could push the company's market cap above $1 trillion if achieved.
- Sales Potential: Flynn anticipates that Eli Lilly's newly launched weight-loss pill Foundayo, combined with Zepbound, could generate approximately $31 billion in U.S. sales next year, with projections rising to $45 billion by 2030, indicating robust revenue growth potential.
- Competition and Risks: Despite CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, Eli Lilly faces increasing competition; however, its strong pipeline in weight-loss drugs and diversification strategy should help maintain its market leadership.
See More
Analyst Sees Significant Upside for Eli Lilly Shares
- Market Leadership: Eli Lilly's dominant position in the weight-loss drug market positions it well for a bright outlook, with analysts projecting significant growth in this sector over the next decade, which is expected to drive solid medium-term growth for the company.
- Sales Growth Potential: Analysts predict that Eli Lilly's weight-loss portfolio, including the newly launched Foundayo and Zepbound, could generate approximately $31 billion in sales in the U.S. next year, potentially rising to $45 billion by 2030, indicating strong revenue growth potential.
- Competitive Risks: Despite facing pressure from competitors, particularly with CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, analysts still believe that the company's robust R&D pipeline in weight-loss drugs provides a competitive edge.
- Diversified Pipeline: Eli Lilly's extensive R&D pipeline in oncology and neuroscience, combined with its strong performance in the weight-loss market, may enhance the company's resilience against competition, further solidifying its market position.
See More
Eli Lilly Expected to Report Strong Q1 Earnings Growth
- Earnings Expectations: Eli Lilly is projected to report Q1 EPS of $6.85 with a 40.3% year-over-year revenue increase to $17.86 billion, indicating strong performance in the obesity treatment market that could drive stock price up.
- Drug Catalysts: Analysts believe that obesity drugs Mounjaro and Zepbound will anchor Lilly's medium-term growth, while the approval of Foundayo and the $7 billion acquisition of Kelonia Therapeutics serve as near-term catalysts that may enhance market confidence.
- Management Guidance: Analyst Stephen Ayers is keenly awaiting management's reaffirmation of the 2026 revenue guidance, as maintaining the current outlook may signal strong market performance for Foundayo, whereas a revision to the lower end could indicate pricing erosion or lagging uptake.
- Market Dynamics: Despite a more than 17% decline in Eli Lilly's stock this year, the company has beaten EPS and revenue estimates 100% of the time over the past two years, maintaining a positive outlook for future performance.
See More
Hims CEO's Pay Gap Sparks Attention Ahead of Vote
- Compensation Structure Analysis: Hims CEO Andrew Dudum's compensation of $22.96 million, down 7% from last year, remains 272 times the median employee pay, highlighting a significant pay gap that may impact the company's governance image.
- Performance Target Achievement: Hims met 94% of its revenue target and 98% of its adjusted EBITDA target last year, resulting in executives receiving 93.72% of their annual incentive bonuses, reflecting stable performance in the highly competitive GLP-1 weight-loss market.
- Stock Award Details: Dudum received 306,406 restricted stock units (RSUs) and performance-based stock options, with options convertible into 278,622 shares at minimum performance and up to 1.39 million shares at maximum performance, indicating the company's focus on long-term incentives.
- Intensifying Market Competition: Hims faces increasing competition in the GLP-1 market from Amazon and other digital platforms, recently expanding access to branded treatments from Novo Nordisk and Eli Lilly to enhance market share and address regulatory pressures.
See More
The Future of AI in Healthcare Applications
- AI in Health Management: Alex Zhavoronkov, founder of Insilico Medicine, advocates for increased consumer use of AI to answer basic health questions like dietary advice, which can save time with doctors and enhance health management efficiency.
- Innovative Health Tools: OpenAI's ChatGPT Health and Amazon's Health AI tools aim to provide data-driven health advice by securely connecting medical records and wellness apps, although these tools are not intended for diagnosis or treatment.
- Accelerated Drug Development: Zhavoronkov notes that AI tools reduce the drug development candidate stage to 18 months, significantly improving efficiency compared to the traditional four years, highlighting AI's immense potential in the pharmaceutical industry.
- Importance of Human Collaboration: Shreehas Tambe from Biocon emphasizes the necessity of
See More
The Future of AI in Healthcare Applications
- AI Health Q&A: Alex Zhavoronkov, CEO of Insilico Medicine, emphasizes that AI can answer basic health questions like dietary advice, thereby saving time spent with doctors and enhancing consumer health management efficiency.
- New Tool Launches: OpenAI and Amazon launched health tools in January, with ChatGPT Health allowing secure connections to medical records, while Amazon's HealthAI provides advice based on medical records and lab results, advancing AI applications in consumer healthcare.
- Reduced R&D Time: Zhavoronkov noted that AI tools cut drug development time to 18 months, significantly improving efficiency compared to the traditional four years, which has crucial strategic implications for the pharmaceutical industry.
- Importance of Human Oversight: Shreehas Tambe, CEO of Biocon, stresses the need for AI models to be validated by professionals to ensure their effectiveness in drug discovery, avoiding erroneous results due to users' unfamiliarity with the technology.
See More
Eli Lilly's Dominance in Weight-Loss Drug Market
- Market Leadership: Eli Lilly's dominance in the weight-loss drug market positions it well for future growth, with projections indicating significant expansion over the next decade, although some investors remain skeptical about its ability to deliver superior returns in the next five years.
- Analyst Optimism: Morgan Stanley analyst Terence Flynn reiterated a 'buy' rating on Eli Lilly stock with a price target of $1,327, suggesting a potential upside of about 52% from the current price of $870, which could push the company's market cap above $1 trillion if achieved.
- Sales Potential: Flynn anticipates that Eli Lilly's newly launched weight-loss pill Foundayo, combined with Zepbound, could generate approximately $31 billion in U.S. sales next year, with projections rising to $45 billion by 2030, indicating robust revenue growth potential.
- Competition and Risks: Despite CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, Eli Lilly faces increasing competition; however, its strong pipeline in weight-loss drugs and diversification strategy should help maintain its market leadership.
See More
Analyst Sees Significant Upside for Eli Lilly Shares
- Market Leadership: Eli Lilly's dominant position in the weight-loss drug market positions it well for a bright outlook, with analysts projecting significant growth in this sector over the next decade, which is expected to drive solid medium-term growth for the company.
- Sales Growth Potential: Analysts predict that Eli Lilly's weight-loss portfolio, including the newly launched Foundayo and Zepbound, could generate approximately $31 billion in sales in the U.S. next year, potentially rising to $45 billion by 2030, indicating strong revenue growth potential.
- Competitive Risks: Despite facing pressure from competitors, particularly with CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, analysts still believe that the company's robust R&D pipeline in weight-loss drugs provides a competitive edge.
- Diversified Pipeline: Eli Lilly's extensive R&D pipeline in oncology and neuroscience, combined with its strong performance in the weight-loss market, may enhance the company's resilience against competition, further solidifying its market position.
See More
